TrialJapanese journal of clinical oncology2025

Obinutuzumab maintenance versus observation for patients with newly diagnosed high tumor burden follicular lymphoma who achieved complete metabolic response after obinutuzumab plus bendamustine induction therapy: a multicenter, randomized, phase III study (JCOG2008, MAIN study).

Tsutomu Kobayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.